Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min). However, the optimal antidepressant dose r...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular psychiatry Vol. 25; no. 7; pp. 1592 - 1603
Main Authors:	Fava, Maurizio, Freeman, Marlene P, Flynn, Martina, Judge, Heidi, Hoeppner, Bettina B, Cusin, Cristina, Ionescu, Dawn F, Mathew, Sanjay J, Chang, Lee C, Iosifescu, Dan V, Murrough, James, Debattista, Charles, Schatzberg, Alan F, Trivedi, Madhukar H, Jha, Manish K, Sanacora, Gerard, Wilkinson, Samuel T, Papakostas, George I
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.07.2020
Subjects:	Adult Antidepressants Antidepressive Agents - therapeutic use Blood pressure Depression - drug therapy Depressive Disorder, Treatment-Resistant - drug therapy Double-Blind Method Double-blind studies Female Glutamic acid receptors (ionotropic) Humans Infusions, Intravenous Intravenous administration Ketamine Ketamine - administration & dosage Ketamine - therapeutic use Male Mental depression Midazolam Middle Aged N-Methyl-D-aspartic acid receptors Placebos Treatment Outcome Treatment resistance
ISSN:	1359-4184, 1476-5578, 1476-5578
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!